ReviewUnited European gastroenterology journal2022
New concepts in the treatment of hepatocellular carcinoma.
Review in United European gastroenterology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Meta-analysis of the value of albumin-bilirubin grading on changes in liver function and its prognostic assessment in patients with hepatocellular carcinoma treated with transhepatic arterial chemoembolization.World journal of surgical oncology · 2025Pooled it
- A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma.BMC gastroenterology · 2025Pooled it
- Salivary Extracellular Vesicles in Detection of Cancers Other than Head and Neck: A Systematic Review.Cells · 2025Pooled it
- Tamoxifen for adults with hepatocellular carcinoma.The Cochrane database of systematic reviews · 2024Pooled it
- An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review.Acta medica academica · 2024Pooled it
- Evaluation of the Efficacy, Safety, and Clinical Outcomes of Ginsenosides as Adjuvant Therapy in Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.Integrative cancer therapiesPooled it
- Artificial intelligence (AI)-assisted full-course case management for primary liver cancer: System design, preliminary implementation, and practical considerations.Global health & medicine · 2026Article
- Neutrophil extracellular traps: A central player in liver diseases.Hepatology communications · 2026Review
- Article
- Surgery-centered integrated strategies for personalized hepatocellular carcinoma care.Cancer biology & medicine · 2026Review
- Psychological and quality of life outcomes associated with multikinase inhibitors versus immune checkpoint inhibitors in advanced hepatocellular carcinoma.Scientific reports · 2026Article
- Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism.Frontiers in pharmacology · 2026Article
- Integrated multi-omics analysis revealed that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth via the Hippo/YAP signaling axis.International journal of surgery (London, England) · 2025Article
- A multimodal LLM-agent framework for personalized clinical decision-making in hepatocellular carcinoma.Patterns (New York, N.Y.) · 2025Article
- Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives.World journal of gastrointestinal oncology · 2025Review
- Mechanisms of ferroptosis in primary hepatocellular carcinoma and progress of artificial intelligence-based predictive modeling in hepatocellular carcinoma.World journal of gastroenterology · 2025Review
- Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma.iLIVER · 2025Review
- L-arginine synergistic with 5-fluorouracil intervenes in DNA damage repair via the DNA-PKcs/ATM/ATR pathway in hepatocellular carcinoma cells.Acta biochimica et biophysica Sinica · 2025Article
- The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine.Molecular cancer · 2025Review
- Yttrium-90 radioembolization for advanced hepatocellular carcinoma with Budd-Chiari syndrome: A case report.World journal of clinical oncology · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death and occurs mainly in the context of chronic liver disease at cirrhosis stage. The Barcelona Clinic Liver Cancer classification, first established in 1999, is the most commonly used staging system for HCC in Western countries that link tumor burden, liver function and performance status with prognosis and therapeutic management. Since the first publication of this classification, it has been implemented in several clinical guidelines and recent major therapeutic advances in the management of HCC have modified the therapeutic landscape of HCC. Accordingly, an updated version was recently published in 2022, incorporating an expert clinical decision-making component and the concept of treatment stage migration. This update also introduces the positive results of recent randomized clinical trials, and introduces atezolizumab/bevacizumab (A/B) as a first-line combination regimen for patients with advanced HCC. Finally, the complexity of the management of patients with HCC highlights the need for a multidisciplinary approach including input from hepatology, surgery, radiology, medical oncology, and radiation oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.